# Predict immune side-effects before they happen and pre-empt them

Source: https://onco.cc/ideas/idea-moon-irae-prediction-and-prevention/  
OnCo record `idea-moon-irae-prediction-and-prevention` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Immunotherapy can trigger dangerous attacks on the gut, lungs or heart. Use blood, gut bacteria and genetic markers to spot who is at risk and act early.

## Summary

Immune-related adverse events cause treatment discontinuation and death, and their management is reactive. Autoantibody profiles, HLA types, microbiome composition, baseline cytokines and early T-cell clonal expansion are each associated with specific toxicities in retrospective series. The proposal is a prospective biomarker cohort across checkpoint inhibitor indications to derive and validate a toxicity risk model, followed by trials of pre-emptive strategies (early steroid-sparing agents, microbiome modulation, intensified monitoring) in high-risk patients.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: A validated model identifies a high-risk group with at least threefold risk of grade 3+ immune toxicity, and pre-emptive management reduces severe events and discontinuations without reducing response rates.
- Rationale: Toxicity and efficacy are partially separable; preventive strategies such as prophylactic vedolizumab or IL-6 blockade have early data suggesting response is preserved.
- Proposed test: Prospective 3,000-patient cohort with banked samples; then a randomised trial of pre-emptive management in model-defined high-risk patients.
- Maturity: preclinical-evidence
- Actor: research

## Sources

- Bottleneck evidence (Toxicity and quality of life are undervalued): Di Maio et al., Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting (JCO 2015): https://doi.org/10.1200/JCO.2014.57.9334

## Connected records

- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- terms: [Immune-related adverse events (irAEs)](https://onco.cc/terms/irae/)
- bottlenecks: [No one can predict who responds to immunotherapy](https://onco.cc/bottlenecks/b-immunotherapy-response/), [Toxicity and quality of life are undervalued](https://onco.cc/bottlenecks/b-toxicity-qol/)
- key papers: [Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials](https://onco.cc/key-papers/paper-di-maio-j-clin-oncol/)

---
JSON: https://onco.cc/api/v1/entities/idea-moon-irae-prediction-and-prevention.json